<DOC>
	<DOCNO>NCT00799890</DOCNO>
	<brief_summary>The investigator hypothesize oral Sunphenon EGCg ( Epigallocatechin-Gallat , EGCG ) treatment - due antiinflamatoric neuroprotective potence - significantly effective oral placebo treatment regard follow parameter : increase brain atrophy , number new T2-lesions cerebral magnetic resonance tomography , reduction NAA/Cr-ratio MR-spectroscopy , progression disability cognitive disorder patient MS .</brief_summary>
	<brief_title>Sunphenon Progressive Forms Multiple Sclerosis</brief_title>
	<detailed_description>The hypothesis study : Sunphenon EGCg antiinflammatoric effect due impact T-cell-proliferation inhibition activity NF-Kb . Sunphenon EGCg neuroprotective effect due antioxidative potence radical scavenger . A 30 month treatment Sunphenon EGCg safe well-tolerated .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<mesh_term>Epigallocatechin gallate</mesh_term>
	<criteria>Primary secondary chronic progressive multiple sclerosis ( m ) EDSS 38 Age 1865 Relapsingremitting m Immunodulatoric immunosuppressive therapy pretreatment Mitoxantron , Natalizumab , Rituximab , Azathioprin &lt; 2 month screen pretreatment Glairameracetat betaInterferons &lt; 4 week screen sign hepatic dysfunction active ulcus ventriculus duodeni neoplasias cure &gt; 1 year screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>primary secondary chronic-progressive</keyword>
	<keyword>sunphenon egcg</keyword>
	<keyword>brain atrophy</keyword>
	<keyword>T2 lesion</keyword>
</DOC>